A Phase 3 interventional study of Atezolizumab and Carboplatin in Urothelial Carcinoma, sponsored by Hoffmann-La Roche. Completed at 204 sites in 35 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-24.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing atezolizumab in Carcinoma, Transitional Cell — 1 open to participants now, 4 under way, 1 of them phase 3. atezolizumab · Carcinoma, Transitional Cell.
Among the 15 studies testing atezolizumab in Carcinoma, Transitional Cell, this one has the largest enrollment, is one of 4 that started in 2016, is one of 3 in phase 3, and was the 4th registered.
632 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.
Browse Carcinoma, Transitional Cell studies →1 of the 15 studies testing atezolizumab in Carcinoma, Transitional Cell is open now, in 1 country. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
By country, each count listing its studies:
atezolizumab: first FDA approval 2016 (TECENTRIQ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 147 Carcinoma, Transitional Cell studies recruiting now, 121 (82%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, atezolizumab is the treatment under test here. Read study by study →
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 3
First in 2015; this study’s year is marked. 4 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,213 is above the median of 50 across 499 interventional studies indexed under Carcinoma, Transitional Cell.
Median enrollment 32 across the 15 interventional studies. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 15 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
12 studies in Carcinoma, Transitional Cell by Hoffmann-La Roche: none open now, 1 under way, none of them phase 3. Of 10 finished, 4 (40%) have results posted.
Among the 12 studies in Carcinoma, Transitional Cell by Hoffmann-La Roche, this one is the only one that started in 2016, is one of 2 in phase 3, and was the 3rd registered.
Hoffmann-La Roche’s Carcinoma, Transitional Cell studies by the year they started, since 2015.
2 of the studies testing atezolizumab in Carcinoma, Transitional Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02989584Memorial Sloan Kettering Cancer CenterA Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer | 2026-12 |
| NCT06161532National Cancer Institute (NCI)Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C... | 2027-11-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies testing atezolizumab in Carcinoma, Transitional Cell, from their registry updates:
Among Hoffmann-La Roche’s 12 in Carcinoma, Transitional Cell:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A Phase III, randomised study of atezolizumab alone and in combination with chemotherapy versus chemotherapy alone in participants with untreated advanced urothelial cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive blinded atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).
Drug: Atezolizumab · Drug: Carboplatin · Drug: Gemcitabine · Drug: Cisplatin
Participants will receive blinded placebo matched to atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).
Drug: Carboplatin · Drug: Gemcitabine · Other: Placebo · Drug: Cisplatin
Eligible participants will receive open-label atezolizumab as monotherapy.
Drug: Atezolizumab
Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1. In specific circumstances treatment may continue beyond disease progression.
Also known as: Tecentriq
Carboplatin will be administered at doses to achieve area under the concentration-time curve (AUC) of 4.5 milligram per milliliter into minute (mg/mL\*min) by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
Gemcitabine will be administered at a dose of 1000 milligrams per square meter (mg/m\^2) by IV infusion on Day 1 and Day 8 of each 21-day cycle, until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
Placebo matched to atezolizumab will be administered by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1. In specific circumstances treatment may continue beyond disease progression.
Cisplatin will be administered at a dose of 70 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
Investigator Assessed Progression-Free Survival (PFS) in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm
PFS is defined as the time from randomization to the first documented disease progression as determined by the investigator with the use of RECIST v1.1, or death from any cause, whichever occurs first.
Time frame: Baseline up to first documented disease progression or death, whichever occurs first (up to approximately 35 months)
Overall Survival (OS) in Atezolizumab+Gemcitabine+Carboplatin/Cisplatin Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
OS is defined as the time from randomization to death due to any cause.
Time frame: Baseline until death due to any cause (up to approximately 73 months)
Overall Survival (OS) in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
OS is defined as the time from randomization to death due to any cause.
Time frame: Baseline until death due to any cause (up to approximately 73 months)
Objective Response Rate (ORR) in Atezolizumab+Gemcitabine+Carboplatin/Cisplatin Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
Objective response rate (ORR) is defined as the proportion of participants with a confirmed objective response, either complete response (CR) or partial response (PR), observed on two assessments \>= 28 days apart per RECIST v1.1, based on investigator assessment. The analysis population for ORR will be all randomized participants with measurable disease at baseline.
Time frame: Baseline up to disease progression, death, or loss of follow-up, whichever occurs first (up to approximately 73 months)
Objective Response Rate (ORR) in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
Objective response rate (ORR) is defined as the proportion of participants with a confirmed objective response, either complete response (CR) or partial response (PR), observed on two assessments \>= 28 days apart per RECIST v1.1, based on investigator assessment. The analysis population for ORR will be all randomized participants with measurable disease at baseline.
Time frame: Baseline up to disease progression, death, or loss of follow-up, whichever occurs first (up to approximately 73 months)
Duration of Response (DOR) in Atezolizumab+Gemcitabine+Carboplatin/Cisplatin Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
Duration of response (DOR) is defined for participants with an objective response as the time from the first documented objective response to documented disease progression per RECIST v1.1, based on investigator assessment, or death due to any cause, whichever occurs first.
Time frame: From first documented objective response (CR or PR) to disease progression, death, or loss of follow-up, whichever occurs first (up to approximately 73 months)
Duration of Response (DOR) in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
Duration of response (DOR) is defined for participants with an objective response as the time from the first documented objective response to documented disease progression per RECIST v1.1, based on investigator assessment, or death due to any cause, whichever occurs first.
Time frame: From first documented objective response (CR or PR) to disease progression, death, or loss of follow-up, whichever occurs first (up to approximately 73 months)
IRF-PFS
Independent review facility PFS (IRF-PFS) is defined as the time from randomization to the first documented disease progression as determined by blinded independent central review with use of RECIST v1.1, or death due to any cause, whichever occurs first.
Time frame: Randomization to first documented disease progression or death from any cause (up to 35 months)
OS Event Free Rate Atezolizumab+Gemcitabine+Carboplatin/Cisplatin Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
Overall Survival (OS) Event Free Rate at 1 Year.
Time frame: Year 1
OS Event Free Rate in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
Overall Survival (OS) Event Free Rate at 1 Year.
Time frame: Year 1
PFS Event Free Rate
Progression Free Survival (PFS) Event Free Rate at Year 1
Time frame: Year 1
Time to Deterioration in Global Health Status as Measured by the EORTC QLQ-C30 Score in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm
Time to deterioration in global health status as measured by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm.
Time frame: Up to approximately 73 months
Time to Deterioration in Global Health Status as Measured by the EORTC QLQ-C30 Score in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab Monotherapy Arm
Time to deterioration in global health status as measured by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 in the Placebo+Chemo Arm versus Atezolizumab Monotherapy Arm.
Time frame: Up to approximately 73 months
Time to Deterioration in Physical Function as Measured by the EORTC QLQ-C30 Score in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm
Median time to deterioration in physical function as measured by the QLQ-C30 in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm.
Time frame: Up to approximately 73 months
Time to Deterioration in Physical Function as Measured by the EORTC QLQ-C30 Score in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab Monotherapy Arm
Median time to deterioration in physical function as measured by the QLQ-C30 in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm versus Atezolizumab Monotherapy Arm.
Time frame: Up to approximately 73 months
Maximum Atezolizumab Serum Concentration
Maximum atezolizumab serum concentration.
Time frame: Cycle 1 Day 1
Minimum Atezolizumab Serum Concentration
Minimum atezolizumab serum concentration.
Time frame: Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 8 Day 1, Cycle 16 Day 1, Cycle 24 Day 1, Cycle 32 Day 1, Day 120 post dose of last blinded atezolizumab treatment, and study drug early discontinuation
Percentage of Participants With Anti-Therapeutic (Anti-Atezolizumab) Antibodies (ATAs)
Percentage of participants with Anti-Therapeutic (Anti-Atezolizumab) Antibodies (ATAs).
Time frame: Up to approximately 35 months
Investigator-Assessed Progression-Free Survival (INV-PFS) in Participants Treated With Atezolizumab Monotherapy Arm Compared With Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
PFS is defined as the time from randomization to the first documented disease progression as determined by the investigator with the use of RECIST v1.1, or death from any cause, whichever occurs first.
Time frame: Baseline up to disease progression, death, or loss of follow-up, whichever occurs first (assessed at baseline, every 9 weeks for 54 weeks and every 12 weeks thereafter up to 35 months)
Percentage of Participants With Grade 3-4 Adverse Events (AEs)
Percentage of participants with Grade 3-4 Adverse Events (AEs) assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0.
Time frame: Baseline up to 93 months
Percentage of Participants With Grade 5 Adverse Events (AEs)
Percentage of participants with Grade 5 Adverse Events (AEs) assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0.
Time frame: Baseline up to 93 months
Percentage of Participants With Serious Adverse Events (SAEs)
Percentage of participants with Serious Adverse Events (SAEs) assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0.
Time frame: Baseline up to 93 months
Percentage of Participants With Adverse Events (AEs) Leading to Withdrawal of Any Study Treatment
Percentage of participants with Adverse Events (AEs) leading to withdrawal of any study treatment assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0.
Time frame: Baseline up to 93 months
Percentage of Participants With Atezolizumab-Specific Adverse Events of Special Interest (AESIs)
Percentage of participants with atezolizumab-specific Adverse Events of Special Interest (AESIs) Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0.
Time frame: Baseline up to 93 months
Participants were enrolled in 221 sites in 35 countries.
| Milestone | Placebo+Gemcitabine+Carboplatin/Cisplatin | Atezolizumab+Gemcitabine+Carboplatin/Cisplatin | Atezolizumab Monotherapy |
|---|---|---|---|
| Started | 400 | 451 | 362 |
| Completed | 0 | 0 | 0 |
| Not completed | 400 | 451 | 362 |
| Withdrew: Lost to follow-up | 10 | 13 | 6 |
| Withdrew: Protocol deviation | 1 | 0 | 0 |
| Withdrew: Symptomatic deterioration | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 39 | 28 | 24 |
| Withdrew: Death | 303 | 332 | 272 |
| Withdrew: Study terminated by sponsor | 47 | 76 | 60 |
| Withdrew: Physician decision | 0 | 1 | 0 |
PFS is defined as the time from randomization to the first documented disease progression as determined by the investigator with the use of RECIST v1.1, or death from any cause, whichever occurs first.
| Months | Placebo+Gemcitabine+Carboplatin/Cisplatin | Atezolizumab+Gemcitabine+Carboplatin/Cisplatin |
|---|---|---|
| Investigator Assessed Progression-Free Survival (PFS) in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm | 6.34 (6.24 to 7.00) | 8.18 (6.51 to 8.34) |
OS is defined as the time from randomization to death due to any cause.
| Months | Placebo+Gemcitabine+Carboplatin/Cisplatin | Atezolizumab+Gemcitabine+Carboplatin/Cisplatin |
|---|---|---|
| Overall Survival (OS) in Atezolizumab+Gemcitabine+Carboplatin/Cisplatin Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm | 13.44 (11.99 to 15.34) | 16.13 (14.19 to 18.76) |
OS is defined as the time from randomization to death due to any cause.
| Months | Placebo+Gemcitabine+Carboplatin/Cisplatin | Atezolizumab Monotherapy |
|---|---|---|
| Overall Survival (OS) in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm | 13.34 (11.89 to 15.61) | 15.21 (13.14 to 17.68) |
Objective response rate (ORR) is defined as the proportion of participants with a confirmed objective response, either complete response (CR) or partial response (PR), observed on two assessments \>= 28 days apart per RECIST v1.1, based on investigator assessment. The analysis population for ORR will be all randomized participants with measurable disease at baseline.
| Percentage of Participants | Placebo+Gemcitabine+Carboplatin/Cisplatin | Atezolizumab+Gemcitabine+Carboplatin/Cisplatin |
|---|---|---|
| Objective Response Rate (ORR) in Atezolizumab+Gemcitabine+Carboplatin/Cisplatin Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm | 44.8 (39.87 to 49.88) | 48.1 (43.38 to 52.84) |
Objective response rate (ORR) is defined as the proportion of participants with a confirmed objective response, either complete response (CR) or partial response (PR), observed on two assessments \>= 28 days apart per RECIST v1.1, based on investigator assessment. The analysis population for ORR will be all randomized participants with measurable disease at baseline.
| Percentage of Participants | Placebo+Gemcitabine+Carboplatin/Cisplatin | Atezolizumab Monotherapy |
|---|---|---|
| Objective Response Rate (ORR) in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm | 44.4 (39.15 to 49.71) | 24.2 (19.89 to 29.01) |
Duration of response (DOR) is defined for participants with an objective response as the time from the first documented objective response to documented disease progression per RECIST v1.1, based on investigator assessment, or death due to any cause, whichever occurs first.
| Months | Placebo+Gemcitabine+Carboplatin/Cisplatin | Atezolizumab+Gemcitabine+Carboplatin/Cisplatin |
|---|---|---|
| Duration of Response (DOR) in Atezolizumab+Gemcitabine+Carboplatin/Cisplatin Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm | 8.15 (6.34 to 8.61) | 9.13 (8.02 to 10.64) |
Duration of response (DOR) is defined for participants with an objective response as the time from the first documented objective response to documented disease progression per RECIST v1.1, based on investigator assessment, or death due to any cause, whichever occurs first.
| Months | Placebo+Gemcitabine+Carboplatin/Cisplatin | Atezolizumab Monotherapy |
|---|---|---|
| Duration of Response (DOR) in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm | 8.11 (6.28 to 8.54) | 29.63 (15.90 to NA) |
Independent review facility PFS (IRF-PFS) is defined as the time from randomization to the first documented disease progression as determined by blinded independent central review with use of RECIST v1.1, or death due to any cause, whichever occurs first.
| Months | Placebo+Gemcitabine+Carboplatin/Cisplatin | Atezolizumab+Gemcitabine+Carboplatin/Cisplatin |
|---|---|---|
| IRF-PFS | 6.34 (6.24 to 8.05) | 7.10 (6.31 to 8.25) |
Overall Survival (OS) Event Free Rate at 1 Year.
| Percentage | Placebo+Gemcitabine+Carboplatin/Cisplatin | Atezolizumab+Gemcitabine+Carboplatin/Cisplatin |
|---|---|---|
| OS Event Free Rate Atezolizumab+Gemcitabine+Carboplatin/Cisplatin Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm | 55.00 (49.98 to 60.02) | 60.00 (55.39 to 64.61) |
Overall Survival (OS) Event Free Rate at 1 Year.
| Percentage | Placebo+Gemcitabine+Carboplatin/Cisplatin | Atezolizumab Monotherapy |
|---|---|---|
| OS Event Free Rate in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm | 54.56 (49.23 to 59.88) | 57.91 (52.72 to 63.10) |
Progression Free Survival (PFS) Event Free Rate at Year 1
| Percentage | Placebo+Gemcitabine+Carboplatin/Cisplatin | Atezolizumab+Gemcitabine+Carboplatin/Cisplatin |
|---|---|---|
| PFS Event Free Rate | 22.17 (17.93 to 26.42) | 30.47 (26.00 to 34.93) |
Time to deterioration in global health status as measured by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm.
| Months | Placebo+Gemcitabine+Carboplatin/Cisplatin | Atezolizumab+Gemcitabine+Carboplatin/Cisplatin |
|---|---|---|
| Time to Deterioration in Global Health Status as Measured by the EORTC QLQ-C30 Score in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm | 12.06 (8.28 to 20.24) | 32.07 (18.40 to NA) |
Time to deterioration in global health status as measured by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 in the Placebo+Chemo Arm versus Atezolizumab Monotherapy Arm.
| Months | Placebo+Gemcitabine+Carboplatin/Cisplatin | Atezolizumab Monotherapy |
|---|---|---|
| Time to Deterioration in Global Health Status as Measured by the EORTC QLQ-C30 Score in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab Monotherapy Arm | 12.02 (8.08 to 20.24) | 23.20 (8.31 to NA) |
Median time to deterioration in physical function as measured by the QLQ-C30 in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm.
| Months | Placebo+Gemcitabine+Carboplatin/Cisplatin | Atezolizumab+Gemcitabine+Carboplatin/Cisplatin |
|---|---|---|
| Time to Deterioration in Physical Function as Measured by the EORTC QLQ-C30 Score in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm | 15.74 (8.28 to 22.57) | 16.39 (9.07 to 26.68) |
Median time to deterioration in physical function as measured by the QLQ-C30 in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm versus Atezolizumab Monotherapy Arm.
| Months | Placebo+Gemcitabine+Carboplatin/Cisplatin | Atezolizumab Monotherapy |
|---|---|---|
| Time to Deterioration in Physical Function as Measured by the EORTC QLQ-C30 Score in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab Monotherapy Arm | 16.10 (8.08 to 22.57) | 9.23 (6.24 to 17.48) |
Maximum atezolizumab serum concentration.
| μg/ mL | Atezolizumab+Gemcitabine+Carboplatin/Cisplatin | Atezolizumab Monotherapy |
|---|---|---|
| Maximum Atezolizumab Serum Concentration | 379 ± 125 | 390 ± 129 |
Minimum atezolizumab serum concentration.
| μg/ mL | Atezolizumab+Gemcitabine+Carboplatin/Cisplatin | Atezolizumab Monotherapy |
|---|---|---|
| Cycle 2 Day 1 | 79.8 ± 52.5 | 80.2 ± 46.0 |
| Cycle 3 Day 1 | 122 ± 47.2 | 129 ± 66.0 |
| Cycle 4 Day 1 | 153 ± 70.4 | 157 ± 63.4 |
| Cycle 8 Day 1 | 216 ± 96.8 | 193 ± 79.8 |
| Cycle 16 Day 1 | 235 ± 103 | 220 ± 79.8 |
| Cycle 24 Day 1 | 244 ± 75.7 | 233 ± 92.5 |
| Cycle 32 Day 1 | 259 ± 97.2 | 258 ± 60.5 |
| Day 120 Post Dose of Last Blinded Atezo Trt | 18.8 ± 36.9 | 9.53 ± 12.7 |
| Study Drug Early Discontinuation | 154 ± 102 | 124 ± 83.8 |
Percentage of participants with Anti-Therapeutic (Anti-Atezolizumab) Antibodies (ATAs).
| Percentage of participants | Atezolizumab+Gemcitabine+Carboplatin/Cisplatin | Atezolizumab Monotherapy |
|---|---|---|
| Baseline evaluable participants | 1.2 | 0.9 |
| Post-baseline evaluable participants | 19.7 | 26.3 |
PFS is defined as the time from randomization to the first documented disease progression as determined by the investigator with the use of RECIST v1.1, or death from any cause, whichever occurs first.
| Months | Placebo+Gemcitabine+Carboplatin/Cisplatin | Atezolizumab Monotherapy |
|---|---|---|
| Investigator-Assessed Progression-Free Survival (INV-PFS) in Participants Treated With Atezolizumab Monotherapy Arm Compared With Placebo+Gemcitabine+Carboplatin/Cisplatin Arm | 6.31 (6.24 to 6.74) | 2.69 (2.20 to 4.04) |
Percentage of participants with Grade 3-4 Adverse Events (AEs) assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0.
| Percentage of Participants | Atezolizumab+Gemcitabine+Carboplatin/Cisplatin | Placebo+Gemcitabine+Carboplatin/Cisplatin | Atezolizumab Monotherapy |
|---|---|---|---|
| Percentage of Participants With Grade 3-4 Adverse Events (AEs) | 84.1 | 84.6 | 46.3 |
Percentage of participants with Grade 5 Adverse Events (AEs) assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0.
| Percentage of Participants | Atezolizumab+Gemcitabine+Carboplatin/Cisplatin | Placebo+Gemcitabine+Carboplatin/Cisplatin | Atezolizumab Monotherapy |
|---|---|---|---|
| Percentage of Participants With Grade 5 Adverse Events (AEs) | 7.5 | 5.7 | 7.9 |
Percentage of participants with Serious Adverse Events (SAEs) assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0.
| Percentage of Participants | Atezolizumab+Gemcitabine+Carboplatin/Cisplatin | Placebo+Gemcitabine+Carboplatin/Cisplatin | Atezolizumab Monotherapy |
|---|---|---|---|
| Percentage of Participants With Serious Adverse Events (SAEs) | 53.7 | 50.6 | 46.0 |
Percentage of participants with Adverse Events (AEs) leading to withdrawal of any study treatment assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0.
| Percentage of Participants | Atezolizumab+Gemcitabine+Carboplatin/Cisplatin | Placebo+Gemcitabine+Carboplatin/Cisplatin | Atezolizumab Monotherapy |
|---|---|---|---|
| Percentage of Participants With Adverse Events (AEs) Leading to Withdrawal of Any Study Treatment | 36.3 | 33.9 | 9.0 |
Percentage of participants with atezolizumab-specific Adverse Events of Special Interest (AESIs) Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0.
| Percentage of Participants | Atezolizumab+Gemcitabine+Carboplatin/Cisplatin | Placebo+Gemcitabine+Carboplatin/Cisplatin | Atezolizumab Monotherapy |
|---|---|---|---|
| Percentage of Participants With Atezolizumab-Specific Adverse Events of Special Interest (AESIs) | 53.3 | 35.5 | 39.5 |
Collected over From the first study drug to the data cutoff date: 9 April 2024 (up to approximately 93 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo+Gemcitabine+Carboplatin/Cisplatin | 303/389 (77.9%) | 197/389 (50.6%) | 379/389 (97.4%) |
| Atezolizumab+Gemcitabine+Carboplatin/Cisplatin | 332/454 (73.1%) | 244/454 (53.7%) | 441/454 (97.1%) |
| Atezolizumab Monotherapy | 272/354 (76.8%) | 163/354 (46%) | 300/354 (84.7%) |
| Event | Placebo+Gemcitabine+Carboplatin/Cisplatin | Atezolizumab+Gemcitabine+Carboplatin/Cisplatin | Atezolizumab Monotherapy |
|---|---|---|---|
| Urinary tract infectionInfections and infestations | 30/389 | 41/454 | 22/354 |
| AnaemiaBlood and lymphatic system disorders | 19/389 | 30/454 | 4/354 |
| ThrombocytopeniaBlood and lymphatic system disorders | 22/389 | 21/454 | 1/354 |
| PneumoniaInfections and infestations | 8/389 | 21/454 | 8/354 |
| PyrexiaGeneral disorders | 12/389 | 18/454 | 9/354 |
| HaematuriaRenal and urinary disorders | 10/389 | 10/454 | 13/354 |
| Acute kidney injuryRenal and urinary disorders | 12/389 | 15/454 | 8/354 |
| Platelet count decreasedInvestigations | 12/389 | 14/454 | 0/354 |
| Febrile neutropeniaBlood and lymphatic system disorders | 9/389 | 14/454 | 0/354 |
| Renal failureRenal and urinary disorders | 2/389 | 3/454 | 8/354 |
| Event | Placebo+Gemcitabine+Carboplatin/Cisplatin | Atezolizumab+Gemcitabine+Carboplatin/Cisplatin | Atezolizumab Monotherapy |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 257/389 | 308/454 | 68/354 |
| NeutropeniaBlood and lymphatic system disorders | 148/389 | 215/454 | 2/354 |
| NauseaGastrointestinal disorders | 181/389 | 202/454 | 43/354 |
| ThrombocytopeniaBlood and lymphatic system disorders | 117/389 | 183/454 | 12/354 |
| Platelet count decreasedInvestigations | 138/389 | 132/454 | 5/354 |
| Neutrophil count decreasedInvestigations | 129/389 | 119/454 | 0/354 |
| Decreased appetiteMetabolism and nutrition disorders | 119/389 | 144/454 | 69/354 |
| FatigueGeneral disorders | 122/389 | 134/454 | 64/354 |
| ConstipationGastrointestinal disorders | 111/389 | 140/454 | 67/354 |
| AstheniaGeneral disorders | 98/389 | 134/454 | 51/354 |
| Age, Continuous(Years) | Placebo+Gemcitabine+Carboplatin/Cisplatin | Atezolizumab+Gemcitabine+Carboplatin/Cisplatin | Atezolizumab Monotherapy | Total |
|---|---|---|---|---|
| Mean | 66.4 ± 9.5 | 67.5 ± 9.7 | 67.0 ± 9.1 | 67.0 ± 9.4 |
| Sex: Female, Male(Participants) | Placebo+Gemcitabine+Carboplatin/Cisplatin | Atezolizumab+Gemcitabine+Carboplatin/Cisplatin | Atezolizumab Monotherapy | Total |
|---|---|---|---|---|
| Female | 102 | 113 | 82 | 297 |
| Male | 298 | 338 | 280 | 916 |
| Ethnicity (NIH/OMB)(Participants) | Placebo+Gemcitabine+Carboplatin/Cisplatin | Atezolizumab+Gemcitabine+Carboplatin/Cisplatin | Atezolizumab Monotherapy | Total |
|---|---|---|---|---|
| Hispanic or Latino | 44 | 41 | 40 | 125 |
| Not Hispanic or Latino | 350 | 402 | 311 | 1063 |
| Unknown or Not Reported | 6 | 8 | 11 | 25 |
| Race (NIH/OMB)(Participants) | Placebo+Gemcitabine+Carboplatin/Cisplatin | Atezolizumab+Gemcitabine+Carboplatin/Cisplatin | Atezolizumab Monotherapy | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 3 | 4 | 2 | 9 |
| Asian | 85 | 90 | 94 | 269 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 1 |
| Black or African American | 0 | 6 | 1 | 7 |
| White | 305 | 346 | 260 | 911 |
| More than one race | 0 | 0 | 1 | 1 |
| Unknown or Not Reported | 7 | 5 | 3 | 15 |
Showing the first 100 of 204 sites across 35 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2016 to primary completion in Aug 2022, 74 months.
Results were first posted in Dec 2023, 1 year 3 months after primary completion.
Of 28 phase 3 interventional studies under Carcinoma, Transitional Cell, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 111. This study's 74 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Atezolizumab · Carboplatin · Gemcitabine · Cisplatin
Carcinoma, Transitional Cell →